Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 28, 2015 11:10 PM ET


Company Overview of aTyr Pharma Inc.

Company Overview

aTyr Pharma, Inc. engages in the discovery and clinical development of protein based therapeutics for patients suffering from severe and rare diseases. The company is developing Resolaris, which is in Phase Ib/II clinical trials in adult patients with facioscapulohumeral muscular dystrophy, a rare genetic myopathy with an immune component. Its products pipeline also includes Resolaris for treatment of patients with early onset facioscapulohumeral muscular dystrophy, a rare genetic myopathy with an immune component and limb-girdle muscular dystrophies, as well as rare pulmonary diseases with an immune component. In addition, the company is developing iMod.Fc, a preclinical immuno-modulatory d...

3545 John Hopkins Court

Suite 250

San Diego, CA 92121

United States

Founded in 2005

53 Employees





Key Executives for aTyr Pharma Inc.

Executive Chairman and Chief Executive Officer
Age: 55
Total Annual Compensation: $410.0K
Chief Medical Officer
Age: 50
Total Annual Compensation: $265.2K
Compensation as of Fiscal Year 2014.

aTyr Pharma Inc. Key Developments

aTyr Pharma Inc. Announces Executive Changes

aTyr Pharma Inc. announced that it will transition oversight of clinical development and operations to Ms. Kelly Blackburn and Melissa Ashlock, M.D. as David Weiner, M.D., transitions from his current position as aTyr's Chief Medical Officer into a clinical advisory role through the end of the first quarter of 2016.

aTyr Pharma, Inc. Announces Resignation of President and Chief Operating Officer Frederic Chereau

aTyr Pharma Inc. announced the resignation of President and Chief Operating Officer Frederic Chereau to pursue other opportunities, effective immediately.

aTyr Pharma Inc.(NasdaqGS:LIFE) added to Russell 2000 Index

aTyr Pharma Inc. will be added to Russell 2000 Index

Similar Private Companies By Industry

Company Name Region
TB Biosciences, Inc. United States
N. American Chem. Corp. United States
MitoSciences Inc. United States
Cytocom, Inc. United States
L1 AgroSciences, Inc. United States

Recent Private Companies Transactions

Private Placement
March 31, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact aTyr Pharma Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at